Braveheart Bio Inc. Common Stock (BRVE)

About BRVE

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Fr…

Employees

49

Website

www.braveheart.bio

Fundamentals

1-day range

$19.83$22.02

Market cap

$—

P/E (trailing)

—

P/E (forward)

-10.73

EPS (trailing)

$-1.25

Dividend yield

—

Beta

-9.67

Avg. volume

559.1K

Latest news

• Braveheart Bio to Participate in Stifel Cardiometabolic Forum
  Yahoo · 9/16/2026

• ORBIMED ADVISORS LLC · August 7, 2026 · Conversion

  40.00M
• ORBIMED ADVISORS LLC · August 7, 2026 · Buy

  273.3K @ $18
• ORBIMED ADVISORS LLC · August 7, 2026 · Buy

  1.67M @ $18
• ORBIMED ADVISORS LLC · August 7, 2026 · Conversion

  9.13M
• Malek David I · August 7, 2026 · Buy

  4.2K @ $18
• Anderson Michele A. · August 7, 2026 · Buy

  1.1K @ $18
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. · August 7, 2026 · Conversion

  32.50M
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. · August 7, 2026 · Conversion

  7.42M
• Forbion Growth Opportunities Fund III Cooperatief U.A. · August 7, 2026 · Conversion

  35.00M
• Forbion Growth Opportunities Fund III Cooperatief U.A. · August 7, 2026 · Conversion

  40.00M
• Forbion Growth Opportunities Fund III Cooperatief U.A. · August 7, 2026 · Buy

  1.68M @ $18
• Forbion Growth Opportunities Fund III Cooperatief U.A. · August 7, 2026 · Buy

  1.92M @ $18
• Forbion Growth Opportunities Fund III Cooperatief U.A. · August 7, 2026 · Conversion

  7.99M
• Forbion Growth Opportunities Fund III Cooperatief U.A. · August 7, 2026 · Conversion

  9.13M
• Murdoch Travis · August 7, 2026 · Buy

  83.3K @ $18